Attune Neurosciences is a neuromodulation company developing AI-guided, personalised TMS protocols designed to modulate specific brain networks rather than applying standardised stimulation parameters. The company's approach uses individual fMRI or EEG-derived brain network maps to determine patient-specific targeting coordinates and protocol parameters for TMS delivery.

The personalised targeting approach is intended to improve response rates in treatment-resistant psychiatric conditions by ensuring stimulation is directed at the specific neural circuit subtype most relevant to the individual patient's disorder, rather than using the same anatomical target for all patients. This aligns with the emerging precision psychiatry paradigm demonstrated by the SAINT protocol for MDD.

Attune targets psychiatrists and neurologists treating patients with treatment-resistant depression, anxiety, and related conditions who have not responded to standard TMS protocols.